Intermountain Healthcare Inks Taiwanese Distribution Deal for NGS Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – US provider Intermountain Healthcare has signed a distribution deal allowing Taiwan's Prisma Biotech to sell the ICG100 tumor sequencing test in that country.

The next-generation sequencing-based ICG100 test provides analyzes 100 genes for patient-specific mutations that could suggest personalized drug treatments. Intermountain controls the rights to the next-generation sequencing-based test through a contract with Prisma's fully-owned subsidiary, ReadGene.

Financial and other details of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.